Skip Navigation



European Heart Journal Advance Access published online on June 2, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn237
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/13/1597    most recent
ehn237v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Leclercq, C.
Right arrow Articles by Mabo, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leclercq, C.
Right arrow Articles by Mabo, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Cardiac resynchronization therapy and atrial fibrillation. Do we have a final answer?

Christophe Leclercq* and Philippe Mabo

Department of Cardiology, Rennes University Hospital, Rennes, France

* Corresponding author. Tel: +33 2 99 28 25 25, Fax: +33 2 99 28 25 10, Email: christophe.leclercq@chu-rennes.fr

This editorial refers to ‘Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation’ by M. Gasparini et al. doi:10.1093/eurheartj/ehn133

The first 150 words of the full text of this article appear below.

Cardiac resynchronization therapy (CRT) has been extensively studied in a variety of clinical trials including >4000 patients in stable sinus rhythm (SR).1 The recently issued European Society of Cardiology guidelines for cardiac pacing and CRT strongly recommend the latter for patients in SR who present with moderate to severe heart failure (HF), left ventricular (LV) systolic dysfunction, and a wide QRS complex, with a view to lower mortality and morbidity. These guidelines assigned a class I, level of evidence A, for the implantation of a CRT pacemaker, and level of evidence B for a CRT intracardiac cardioverter defibrillator (ICD).1 Surprisingly, despite the high prevalence of permanent atrial fibrillation (AF) observed among patients suffering from moderate to severe HF, CRT has not been tested in a large, randomized clinical trial dedicated to patients in permanent AF. The likelihood of co-existent AF and chronic HF is strongly related to the severity of . . . [Full Text of this Article]

CRT in the presence of AF

Observational studies
Randomized trials

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation
Maurizio Gasparini, Angelo Auricchio, Marco Metra, François Regoli, Cecilia Fantoni, Barbara Lamp, Antonio Curnis, Juergen Vogt, Catherine Klersy, and for the Multicentre Longitudinal Observational Study (MILOS) Group
EHJ 2008 29: 1644-1652. [Abstract] [FREE Full Text]